Works matching IS 13685031 AND DT 2012 AND VI 66 AND IP 8


Results: 15
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.

    Published in:
    International Journal of Clinical Practice, 2012, v. 66, n. 8, p. 731, doi. 10.1111/j.1742-1241.2012.02975.x
    By:
    • Gomis, R.;
    • Owens, D. R.;
    • Taskinen, M.-R.;
    • Del Prato, S.;
    • Patel, S.;
    • Pivovarova, A.;
    • Schlosser, A.;
    • Woerle, H.-J.
    Publication type:
    Article
    13
    14
    15